T-CURX Secures $20M Series A to Advance Non-Viral CAR-T Cancer Therapies
December 21, 2025, 9:33 am
German biotech T-CURX closed a $20 million Series A funding round. The Würzburg-based company will accelerate clinical development of its non-viral CAR-T cell therapies. These innovative treatments target acute myeloid leukemia (AML) and solid tumors. Funds also advance proprietary non-viral technologies for in vivo CAR-T generation. BiomedVC led the syndicate. This investment propels next-generation cancer immunotherapy, aiming for scalable, cost-effective global access. It signifies a major leap in precision oncology.
Würzburg, Germany, stands at the forefront of cancer innovation. Biotech firm T-CURX announced a major financial milestone. The company secured $20 million in its Series A financing. This investment fuels critical advancements in cancer treatment.
The funding round saw strong international participation. BiomedVC spearheaded the syndicate. Key investors included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund. Existing and new individual investors also contributed. This broad support underscores confidence in T-CURX’s mission.
T-CURX is developing next-generation CAR-T cell therapies. These treatments represent a significant shift in oncology. They harness the patient's own immune system. Engineered T cells target and destroy cancer cells. This approach offers profound hope for patients.
The new capital has clear objectives. It will accelerate clinical development. T-CURX focuses on non-viral CAR-T therapies. These are aimed at two challenging areas: Acute Myeloid Leukemia (AML) and solid tumor indications. Both present high unmet medical needs.
Beyond clinical trials, funds advance proprietary technologies. T-CURX seeks to perfect in vivo CAR-T generation. This means creating CAR-T cells directly within the body. It simplifies the manufacturing process. It also broadens patient access.
T-CURX’s innovation lies in its non-viral approach. Traditional CAR-T therapies often use viruses. These viruses deliver genetic material into T cells. T-CURX employs virus-free methods. They use Sleeping-beauty transposon gene transfer. This technique precisely modifies T cells.
This non-viral strategy offers distinct advantages. It enables scalable manufacturing. Production costs can decrease significantly. This is crucial for wider adoption of CAR-T treatments. Affordability remains a barrier for many patients globally. T-CURX aims to dismantle this barrier.
The company emerged from the University Clinics Würzburg. Prof. Michael Hudecek co-founded T-CURX. He is a recognized pioneer. His work focuses on non-viral CAR-T cell therapies. Ulf Grawunder, PhD, serves as CEO. His leadership drives the company’s ambitious goals.
Their mission is clear. Bring effective CAR-T cell therapies to more cancer patients. These therapies must be both cost-effective and scalable. The ultimate goal is to "democratize" CAR-T treatments. Global accessibility is a primary objective.
The European oncology and immuno-oncology landscape remains dynamic. Investment activity in 2025 shows steady, selective growth. T-CURX's Series A round stands out. It represents one of the larger early-stage raises in the sector.
Other European firms also secured significant funding. Hedera Dx in Switzerland raised €15 million. Their platform focuses on precision oncology diagnostics. Finland's TILT Biotherapeutics garnered €22.6 million. They advance immuno-oncology candidates for solid tumors. BIMINI Biotech in the Netherlands closed a €3 million Seed round. They develop small-molecule therapies for hematological cancers.
Collectively, these rounds inject substantial capital into cancer research. They total approximately €58 million in disclosed funding. This indicates robust investor interest. Innovation in cancer therapy continues to attract major investment. T-CURX is a significant part of this trend.
The promise of CAR-T therapy is immense. It transforms outcomes for some blood cancers. Extending this success to solid tumors is the next frontier. T-CURX’s technology targets this challenge. Its non-viral platform offers a unique pathway.
The Sleeping-beauty transposon system is key. It allows efficient gene transfer. This process bypasses viral vectors. It reduces complexity. It enhances safety profiles. These attributes are vital for regulatory approval and widespread use.
This $20 million infusion positions T-CURX strongly. It accelerates critical research. It moves new therapies closer to patients. The fight against cancer gains a powerful new ally. T-CURX leads the charge for accessible, advanced cancer care. The future of immunotherapy looks brighter.
Würzburg, Germany, stands at the forefront of cancer innovation. Biotech firm T-CURX announced a major financial milestone. The company secured $20 million in its Series A financing. This investment fuels critical advancements in cancer treatment.
The funding round saw strong international participation. BiomedVC spearheaded the syndicate. Key investors included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund. Existing and new individual investors also contributed. This broad support underscores confidence in T-CURX’s mission.
T-CURX is developing next-generation CAR-T cell therapies. These treatments represent a significant shift in oncology. They harness the patient's own immune system. Engineered T cells target and destroy cancer cells. This approach offers profound hope for patients.
The new capital has clear objectives. It will accelerate clinical development. T-CURX focuses on non-viral CAR-T therapies. These are aimed at two challenging areas: Acute Myeloid Leukemia (AML) and solid tumor indications. Both present high unmet medical needs.
Beyond clinical trials, funds advance proprietary technologies. T-CURX seeks to perfect in vivo CAR-T generation. This means creating CAR-T cells directly within the body. It simplifies the manufacturing process. It also broadens patient access.
T-CURX’s innovation lies in its non-viral approach. Traditional CAR-T therapies often use viruses. These viruses deliver genetic material into T cells. T-CURX employs virus-free methods. They use Sleeping-beauty transposon gene transfer. This technique precisely modifies T cells.
This non-viral strategy offers distinct advantages. It enables scalable manufacturing. Production costs can decrease significantly. This is crucial for wider adoption of CAR-T treatments. Affordability remains a barrier for many patients globally. T-CURX aims to dismantle this barrier.
The company emerged from the University Clinics Würzburg. Prof. Michael Hudecek co-founded T-CURX. He is a recognized pioneer. His work focuses on non-viral CAR-T cell therapies. Ulf Grawunder, PhD, serves as CEO. His leadership drives the company’s ambitious goals.
Their mission is clear. Bring effective CAR-T cell therapies to more cancer patients. These therapies must be both cost-effective and scalable. The ultimate goal is to "democratize" CAR-T treatments. Global accessibility is a primary objective.
The European oncology and immuno-oncology landscape remains dynamic. Investment activity in 2025 shows steady, selective growth. T-CURX's Series A round stands out. It represents one of the larger early-stage raises in the sector.
Other European firms also secured significant funding. Hedera Dx in Switzerland raised €15 million. Their platform focuses on precision oncology diagnostics. Finland's TILT Biotherapeutics garnered €22.6 million. They advance immuno-oncology candidates for solid tumors. BIMINI Biotech in the Netherlands closed a €3 million Seed round. They develop small-molecule therapies for hematological cancers.
Collectively, these rounds inject substantial capital into cancer research. They total approximately €58 million in disclosed funding. This indicates robust investor interest. Innovation in cancer therapy continues to attract major investment. T-CURX is a significant part of this trend.
The promise of CAR-T therapy is immense. It transforms outcomes for some blood cancers. Extending this success to solid tumors is the next frontier. T-CURX’s technology targets this challenge. Its non-viral platform offers a unique pathway.
The Sleeping-beauty transposon system is key. It allows efficient gene transfer. This process bypasses viral vectors. It reduces complexity. It enhances safety profiles. These attributes are vital for regulatory approval and widespread use.
This $20 million infusion positions T-CURX strongly. It accelerates critical research. It moves new therapies closer to patients. The fight against cancer gains a powerful new ally. T-CURX leads the charge for accessible, advanced cancer care. The future of immunotherapy looks brighter.